860 related articles for article (PubMed ID: 16841178)
61. Sequential hormone therapy with medroxyprogesterone acetate for 7, 12-dimethylbenz [alpha] anthracene-induced rat mammary tumors.
Iino Y; Ishikawa H; Izuo M; Takikawa H
Jpn J Clin Oncol; 1989 Mar; 19(1):45-50. PubMed ID: 2522157
[TBL] [Abstract][Full Text] [Related]
62. Cardiovascular risk assessment with oxidised LDL measurement in postmenopausal women receiving intranasal estrogen replacement therapy.
Kurdoglu M; Yildirim M; Kurdoglu Z; Erdem A; Erdem M; Bilgihan A; Goktas B
Gynecol Endocrinol; 2011 Aug; 27(8):551-7. PubMed ID: 20670096
[TBL] [Abstract][Full Text] [Related]
63. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
64. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
Xu B; Kitawaki J; Koshiba H; Ishihara H; Kiyomizu M; Teramoto M; Kitaoka Y; Honjo H
Maturitas; 2007 Feb; 56(2):142-52. PubMed ID: 16962266
[TBL] [Abstract][Full Text] [Related]
65. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
66. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
67. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.
Katsuki Y; Shibutani Y; Aoki D; Nozawa S
Cancer; 1997 Jan; 79(1):169-76. PubMed ID: 8988742
[TBL] [Abstract][Full Text] [Related]
68. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells.
Ruan X; Schneck H; Schultz S; Fehm T; Cahill MA; Seeger H; Chen R; Yu Q; Mueck AO; Neubauer H
Gynecol Endocrinol; 2012 Nov; 28(11):863-6. PubMed ID: 22494101
[TBL] [Abstract][Full Text] [Related]
69. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence.
Prior JC
Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):495-501. PubMed ID: 26512775
[TBL] [Abstract][Full Text] [Related]
70. Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene.
Nielsen M; Raundahl J; Pettersen PC; Loog M; Karemore G; Karsdal MA; Christiansen C
Menopause; 2009; 16(4):785-91. PubMed ID: 19322115
[TBL] [Abstract][Full Text] [Related]
71. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
72. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
[TBL] [Abstract][Full Text] [Related]
73. Hormone replacement therapy and breast cancer risk.
Gambrell RD
Arch Fam Med; 1996 Jun; 5(6):341-8. PubMed ID: 8640324
[TBL] [Abstract][Full Text] [Related]
74. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
75. Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women.
Cheng G; Butler R; Warner M; Gustafsson JÅ; Wilczek B; Landgren BM
Menopause; 2013 May; 20(5):496-503. PubMed ID: 23615640
[TBL] [Abstract][Full Text] [Related]
76. Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women.
Karaflou M; Kaparos G; Rizos D; Creatsa M; Christodoulakos G; Lambrinoudaki I
Fertil Steril; 2010 Nov; 94(6):2399-401. PubMed ID: 20493474
[TBL] [Abstract][Full Text] [Related]
77. Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women.
Hermenegildo C; Oviedo PJ; Laguna A; García-Pérez MA; Tarín JJ; Cano A
Menopause; 2008; 15(4 Pt 1):714-7. PubMed ID: 18340278
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
79. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.
Casanova G; Spritzer PM
Lipids Health Dis; 2012 Oct; 11():133. PubMed ID: 23046709
[TBL] [Abstract][Full Text] [Related]
80. Breast cancer risk in postmenopausal women using estrogen-only therapy.
Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2006 Dec; 108(6):1354-60. PubMed ID: 17138766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
